CL2014001126A1 - Pharmaceutical composition useful as a vaccine against Escherichia coli bacteria producing shigatoxins (stec), comprising at least one antigen or an immunogenic outer membrane protein or associated immunogenic protein and conserved in stec strains. - Google Patents

Pharmaceutical composition useful as a vaccine against Escherichia coli bacteria producing shigatoxins (stec), comprising at least one antigen or an immunogenic outer membrane protein or associated immunogenic protein and conserved in stec strains.

Info

Publication number
CL2014001126A1
CL2014001126A1 CL2014001126A CL2014001126A CL2014001126A1 CL 2014001126 A1 CL2014001126 A1 CL 2014001126A1 CL 2014001126 A CL2014001126 A CL 2014001126A CL 2014001126 A CL2014001126 A CL 2014001126A CL 2014001126 A1 CL2014001126 A1 CL 2014001126A1
Authority
CL
Chile
Prior art keywords
stec
immunogenic
protein
escherichia coli
shigatoxins
Prior art date
Application number
CL2014001126A
Other languages
Spanish (es)
Inventor
Mauricio Vidal Alvarez Roberto
Carlos Salazar Garrido Juan
Antonio Del Canto Fuentes Felipe
Arturo Montero Forero David
Original Assignee
Univ Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chile filed Critical Univ Chile
Priority to CL2014001126A priority Critical patent/CL2014001126A1/en
Publication of CL2014001126A1 publication Critical patent/CL2014001126A1/en
Priority to PCT/CL2015/000026 priority patent/WO2015164989A1/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Existen distintas cepas de Escherichia coli que producen shigatoxina (STEC), asociados a enfermedades transmitidas por alimentos, y que pueden producir Síndrome Urémico Hemolítico (SUH). La invención corresponde a antígenos como vacunas, que son reconocidas por suero de pacientes que cursaron con SUH y reconocidas tanto por IgG como IgA.There are different strains of Escherichia coli that produce shigatoxin (STEC), associated with foodborne diseases, and that can produce Hemolytic Uremic Syndrome (HUS). The invention corresponds to antigens such as vaccines, which are recognized by serum of patients who studied with HUS and recognized by both IgG and IgA.

CL2014001126A 2014-04-29 2014-04-29 Pharmaceutical composition useful as a vaccine against Escherichia coli bacteria producing shigatoxins (stec), comprising at least one antigen or an immunogenic outer membrane protein or associated immunogenic protein and conserved in stec strains. CL2014001126A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CL2014001126A CL2014001126A1 (en) 2014-04-29 2014-04-29 Pharmaceutical composition useful as a vaccine against Escherichia coli bacteria producing shigatoxins (stec), comprising at least one antigen or an immunogenic outer membrane protein or associated immunogenic protein and conserved in stec strains.
PCT/CL2015/000026 WO2015164989A1 (en) 2014-04-29 2015-04-24 Immunogenic bacterial proteins, pharmaceutical compositions containing same, and vaccines against shiga-toxin-producing escherichia coli

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL2014001126A CL2014001126A1 (en) 2014-04-29 2014-04-29 Pharmaceutical composition useful as a vaccine against Escherichia coli bacteria producing shigatoxins (stec), comprising at least one antigen or an immunogenic outer membrane protein or associated immunogenic protein and conserved in stec strains.

Publications (1)

Publication Number Publication Date
CL2014001126A1 true CL2014001126A1 (en) 2014-08-29

Family

ID=52002355

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014001126A CL2014001126A1 (en) 2014-04-29 2014-04-29 Pharmaceutical composition useful as a vaccine against Escherichia coli bacteria producing shigatoxins (stec), comprising at least one antigen or an immunogenic outer membrane protein or associated immunogenic protein and conserved in stec strains.

Country Status (2)

Country Link
CL (1) CL2014001126A1 (en)
WO (1) WO2015164989A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220233672A1 (en) * 2019-05-31 2022-07-28 Universidad De Chile An immunogenic formulation that induces protection against shiga toxin-producing escherichia coli (stec)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002355074A (en) * 2001-01-24 2002-12-10 Univ Tsukuba Nucleic acid molecule and polypeptide specific to enteropathogenic escherichia coli o157:h7 and method for using the same
EP1580195A1 (en) * 2004-03-26 2005-09-28 Mutabilis SA Compositions of polypeptides specific to pathogenic ExPEC E. coli strains and their use as vaccines and in immunotherapy
HUE027400T2 (en) * 2005-02-18 2016-10-28 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
US20120263724A1 (en) * 2005-04-20 2012-10-18 Manohar John Escherichia coli o157:h7 proteins and uses thereof
EP2586790A3 (en) * 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
GB0720250D0 (en) * 2007-10-17 2007-11-28 Univ Edinburgh Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof
WO2010115278A1 (en) * 2009-04-06 2010-10-14 University Of Saskatchewan Methods and compositions for treating and preventing shiga toxin-producing escherichia coli infection
SG177533A1 (en) * 2009-07-07 2012-02-28 Novartis Ag Conserved escherichia coli immunogens
GB0917002D0 (en) * 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Improved shigella blebs

Also Published As

Publication number Publication date
WO2015164989A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
MX2022010376A (en) De-immunized shiga toxin a subunit effector polypeptides for applications in mammals.
NI201800052A (en) ANTIBODIES THAT NEUTRALIZE THE HUMAN SYNCITIAL RESPIRATORY VIRUS
AR089797A1 (en) VACCINES AGAINST CLOSTRIDUM DIFFICILE THAT INCLUDE RECOMBINANT TOXINS
EP4272750A3 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
EP3616716A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
BR112012022800A2 (en) immunogenic composition or vaccine, genetically engineered gram-negative bacterial strain, methods for treating or preventing infection or disease, for producing an immunogenic composition or vaccine, and for preparing an immunoglobulin, immunoglobulin preparation, and pharmaceutical preparation
MX2019003682A (en) Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same.
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
CY1119957T1 (en) TREATMENT OF PATIENTS WITH THE USE OF ANNOUNCED PHARMACEUTICAL PREPARATION
BR112014032636A2 (en) ATENUATED STREPTOCOCCUS SUIS VACCINES AND PRODUCTION METHODS AND THEIR USES
CL2017000625A1 (en) Immunogenic / therapeutic glycoconjugate compositions and their uses
BR112012008338A2 (en) combination of vaccines against respiratory tract diseases.
EA201891124A2 (en) NEW FLOURED ADJUVANTS AND DELIVERY SYSTEMS
PH12015501716A1 (en) Anti-mycoplasma spp. subunit vaccine
BR112015004463A2 (en) hyperbaric device and processes for producing inactivated vaccines and for refolding / solubilizing recombinant proteins
MX349657B (en) Protein matrix vaccine compositions including polycations.
BR112015022582A2 (en) nucleic acid molecule, plasmid, vaccine, and use of a plasmid
BR112016006210A2 (en) flu therapy and vaccine
PH12015502844B1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
BR112015023738B8 (en) INFLUENZA NUCLEOPROTEIN VACCINES
BR112014020025A2 (en) rotavirus subunit vaccines and methods of production and use thereof
CL2014001126A1 (en) Pharmaceutical composition useful as a vaccine against Escherichia coli bacteria producing shigatoxins (stec), comprising at least one antigen or an immunogenic outer membrane protein or associated immunogenic protein and conserved in stec strains.
BR112018074107A2 (en) method for reducing egg contamination
PH12016502529A1 (en) Influenza vaccine nasal vaccination system
GB2515222A (en) Use of flagellin as a vaccine